The Golden Jubilee of vaccination against poliomyelitis

Indian Journal of Medical Research

Volumn 119, Issue 1, 2004, Pages 1-17

  John, T Jacob ^a  

^a NONE   (India)

Author keywords

Inactivated poliovirus vaccine; Oral polio vaccine; Poliomyelitis

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B POLIOMYELITIS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PLACEBO; POLIOMYELITIS VACCINE; RABIES VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

BIOTECHNOLOGY; CLINICAL RESEARCH; CLINICAL TRIAL; DEVELOPING COUNTRY; DIPHTHERIA; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG USE; ENCEPHALOMYELITIS; EPIDEMIC; ERADICATION THERAPY; EUROPE; GENETIC STABILITY; HEALTH CARE COST; HEALTH ECONOMICS; HEPATITIS B; HERD IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INDIA; INDUSTRIALIZATION; INFLUENZA; INFLUENZA VACCINATION; LICENSING; MEASLES; MEASLES VACCINATION; NONHUMAN; PARALYSIS; PERTUSSIS; PHYSIOTHERAPY; POLICY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PROTECTION; RABIES; REVERTANT; REVIEW; SCIENCE; SMALLPOX; TETANUS; TETANUS PROPHYLAXIS; UNITED STATES; VACCINATION; WILD TYPE; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

BIOTECHNOLOGY; HISTORY, 20TH CENTURY; HUMANS; IMMUNITY; INDIA; INFANT; INFANT, NEWBORN; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 1342326709     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Salk JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 1953; 151: 1081-98.
2. Salk JE, Bennett BL, Lewis LJ, Bazeley PL, Krech V, Ward EN, et al. Studies in human subjects on active immunization against poliomyelitis. II. A practical means of inducing and maintaining antibody formation. Am J Public Health 1954; 44: 994-1009.
3. Sabin AB. Present position of immunization against poliomyelitis with live virus vaccines. BMJ 1959; 1: 663-80.
4. van Wezel AL, van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 1978; 41: 159-68.
5. Smith JS. Patenting the Sun. Polio and the Salk Vaccine. New York: Bantam Doubleday Dell Publishing Group; 1991 p. 1-414.
6. Robbins FC. The history of polio vaccine development. Vaccines. 3rd ed. In: Plotkin SA, Orenstein WA, editors. 1999 p. 13-27.
7. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949; 109: 85-7.
8. Salk JE. Recent studies on immunization against poliomyelitis. Pediatrics 1953; 12: 471-82.
9. Plotkin SA, Murdin A, Vidor E. Inactivated polio vaccine. Vaccines. 3rd ed. In: Plotkin SA, Orenstein WA editors. 1999 p. 345-63.
10. Salk JE, Krech U, Youngner JS, Bennet BL, Lewis LJ, Brazeley PL. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health 1954; 44: 563-70.
11. Shorter E. The Health Century. New York: Doubleday; 1987 p. 60-70.
12. Nathanson N, Langmuir AD. The Cutter incident: Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am J Hyg 1963; 78: 29-60.
13. Oral poliomyelitis vaccines. Report of Special Advisory Committee on Oral Poliomyelitis to the Surgeon General of the Public Health Service. J Am Med Assoc 1964; 190: 161-4.
14. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunisation Practices. MMWR Recomm Rep 1997; 46(RR 3): 1-25.
15. Lapinleimu K, Stenvik M. The efficacy of polio vaccination in Finland. Dev Biol Stand 1978; 41: 137-9.
16. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis 1984; 6(Suppl 2): S457-60.
17. Bottiger M. The elimination of polio in the Scandinavian countries. Public Health Rev 1993-94: 21 (1,2): 27-33.
18. Magrath DI, Evans DM, Ferguson M, Schild GC, Minor PD, Horand F. Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. J Gen Virol 1986; 67: 899-905.
19. van Wezel AL, van der Velden-de- Groot CAM. Large-scale cultivation of animal cells in microcarrier culture. Process Biochem 1978; 13: 6-8.
20. van Wezel AL, van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 1978; 41: 159-68.
21. van Wezel AL, van Herwaarden JAM, van de Heuvel-de Rijk EW. Large scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated. Dev Biol Stand 1979; 42: 65-9.
22. Van Steenis G, van Wezel AL. Killed poliovaccine: An evaluation of safety testing. Dev Biol Stand 1981; 47: 143-50.
23. Van Steenis G, van Wezel AL, Sekhuis VM. Potency testing of killed polio vaccine in rats. Dev Biol Stand 1981; 47: 119-28.
24. Montagnon BJ, Fanget B, Nicholas AJ. The large scale cultivation of VERO cells in microcarrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981; 47: 55-64.
25. Montagnon BJ, Fanget B, Vincent-Falquet JC. Industrial scale production of inactivated poliovirus vaccine prepared by culture of vero cells on microcarrier. Rev Infect Dis 1984; 6 (Suppl 2): S341-4.
26. Van Wezel AL, Van Steenis G, Van Der Marel P, Osterhaus AD. Inactivated poliovirus vaccine: Current production methods and new developments. Rev Infect Dis 1984; 6 (suppl 2): S335-40.
27. John TJ. Immunisation against polioviruses in developing countries. Rev Med Virol 1993; 3: 149-60.
28. Van Seefried A, Chun JH, Grant JA, Letvenuk L, Pearson EW. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. Rev Infect Dis 1984; 6 (Suppl 2): S345-9.
29. Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985; 139: 977-80.
30. Simoes EA, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand 1986; 14: 127-31.
31. Melnick J, Benyesh-Melnick M, Pena R, Yow M. Effectiveness of Salk vaccine. JAMA 1961; 175: 1159-62.
32. Bottiger M. Polio immunity to killed vaccine: An 18-year follow up. Vaccine 1990; 8: 443-5.
33. Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunised with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 1993; 168: 452-4.
34. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997; 16: 312-22.
35. Oduntan SO, Lucas AO, Wennen EM. The immunological response of Nigerian infants to attenuated and inactivated poliovaccines. Ann Trop Med Parasitol 1978; 72: 111-5.
36. Krishnan R, Jadhav M, Selvakumar R, John TJ. Immune response of infants in tropics to injectable poliovaccine. BMJ 1982; 284: 164-5.
37. Krishnan R, Jadhav M, John TJ. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 1983; 61: 689-92.
38. Kok PW, Leeuwenburg J, Tukei P, van Wezel AL, Kapsenberg JG, van Steenis G, et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ 1992; 70: 93-103.
39. Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993; 341: 1545-50.
40. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000; 343: 767-73.
41. Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Bull World Health Organ 1996; 74: 253-68.
42. Samuel BU, Cherian T, Sridharan G, Mukundan P, John TJ. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991; 338: 343-4.
43. Samuel BU, Cherian T, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992; 10: 135.
44. Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabreteste B, Sow A, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; i: 897-9.
45. John TJ, Samuel R, Balraj , John R. Disease surveillance at district level: A model for developing countries. Lancet 1998; 352: 58-61.
46. John TJ, Selvakumar R, Balraj V, Rajarathinam A. Field studies using killed poliovirus vaccine. In: Proceedings of the Third International Seminar on Vaccination in Africa, Niger. Paris: Association for the Promotion of Preventive Medicine; 1987 p. 173-81.
47. John TJ, Understanding the scientific basis of preventing polio by immunization. Pioneering contributions from India. Proc Indian Natl Sci Acad 2003; B 69: 393-422.
48. John TJ, Devarajan LV. Poliovirus antibody in milk and sera of lactating women. Indian J Med Res 1973; 61: 1009-12.
49. John TJ, Devarajan LV, Luther L, Vijayarathnam P. Effect of breast feeding on seroresponse of infants to oral poliovirus vaccination. Pediatrics 1976; 57: 47-53.
50. Hanson L, Carlsson B, Jalil F, Lindblad BS, Khan SR, Van Wezel AL et al. Different secretory IgA antibody responses after immunisation with inactivated and live poliovirus vaccines. Rev Infect Dis 1984; 6 (Suppl 2): S356-60.
51. Plotkin SA, Katz M, Brown RE, Pagano JS. Oral poliovirus vaccination in newborn African infants. The inhibitory effect of breast-feeding. Am J Dis Child 1966; 111: 27-30.
52. Ogra PL, Karzon DT, Righthand F, MacGillyrragm Immunoglobulin response in serum and secretions after immunisation with live and inactivated poliovirus vaccines and natural infection. N Engl J Med 1968; 279: 893-900.
53. Onorato IM, Modlin JF, McBean AM, Thomas ML, Losonsky GA, Bernier RH, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163: 1-6.
54. Faden H, Modlin JF, Thomas ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. J Infect Dis 1990; 162: 1291-7.
55. Faden H, Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Am J Dis Child 1992; 146: 1320-3.
56. Robbins FC, Nightingale EO. Poliomyelitis. In: Walsh JA, Warren KS, editors. Strategies for Primary Health Care Technologies Appropriate for the Control of Diseases in the Developing World. Chicago: University of Chicago Press; 1986 p. 189-202.
57. Brooks GF, Butel JS, Ornston LN. Picornaviruses. In: Jawetz, Melnick and Adelberg's Medical Microbiology. London: Prentice Hall International; 1991 p. 410-23.
58. Jamison DT, Torres AM, Chen LC, Melnick JL. In: Jamison DT, Mosley WH, Measham AR, Bobadilla JL, Editors. 1993 p. 117-29.
59. Hull HF, Ward NA, Hull BP, Milstien JB, de Quadros C. Paralytic poliomyelitis: Seasoned strategies, disappearing disease. Lancet 1994; 343: 1331-7.
60. John TJ. Anomalous observations on IPV and OPV vaccination. Dev Biol 2001; 105: 197-208.
61. Selvakumar R, John TJ. Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 1987; 5: 141-4.
62. Trollfors B, Taranger J, Lagergard T, Sundh V, Bryla DA, Schneerson R, et al. Immunisation of children with pertussis toxoids decreases spread of pertussis within the family. Pediatr Infect Dis J 1998; 17: 196-9.
63. Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV. Influenza vaccination of health care workers in long-term care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175: 1-6.
64. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Munay GD, et al. Effect of influenza vaccination of health care, workers on mortality of elderly people in long-term care: A randomised control trial. Lancet 2000; 355: 93-7.
65. Oshitani H, Saito R, Seki N, Tanabe N, Yamazaki O, Mayashi S. et al. Influenza vaccination levels and influeza-like illness in long-term care facilities for elderly people in Niigata, Japan, during an influenza A (H3N2) epidemic. Infect Control Hosp Epidemiol 2000; 21: 728-30.
66. Ward JI, Zangwill KM. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA, Editors. Vaccines, Third ed. Philadelphia: WB Saunders Co.; 1999 p. 183-221.
67. John TJ, Samuel R. Herd immunity and herd effect: New insights and definitions. Eur J Epidemiol 2000; 16: 601-6.
68. Stickle G. Observed and expected poliomyelitis in the United States, 1958-1961. Am J Public Health 1964; 54: 1222-9.
69. Chin TD, Marine WM. The changing pattern of poliomyelitis in two urban epidemics. Public Health Rep 1961; 76: 553-63.
70. Schonberger LB, Kaplan J, Kim-Farley R, Moore M, Eddins DL, Hatch M. Control of paralytic poliomyelitis in the United States. Rev Infect Dis 1984; 6 (Suppl 2): S424-6.
71. WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine. Results of a ten-year enquiry. Bull World Health Organ 1982; 60: 231-42.
72. Hofman B. Poliomyelitis in the Netherlands before and after immunisation with inactivated poliovaccine. J Hyg 1967; 65: 547-57.
73. Oostvogel R, van Wijngaarden J, vender Avoort HG, Mulders MN, Conyn-Van Spacndonck MA, Runke HC. Poliomyelitis outbreak in an unvaccinated community in the Netherlands. Lancet 1994; 344: 665-70.
74. Bijkerk H. Poliomyelitis in the Netherlands. Dev Biol Stand 1997; 43: 195-206.
75. Andre FE. Control of poliomyelitis by vaccination in Belgium. Rev Infect Dis 1984; 6 (Suppl 2): S419-23.
76. Drucker J. Poliomyelitis in France: Epidemiology and vaccination status. Pediatr Infect Dis J 1991; 10: 967-9.
77. Malvy DJ, Drucker J. Elimination of poliomyelitis in France: Epidemiology and vaccine status. Public Health Rev 1993-94; 21: 41-9.
78. Capiau C, Poolman J, Hoet B, Bogaerts H, Andre F. Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: Difficulties encountered and lessons learned. Vaccine 2003; 21: 2173-87.
79. American Academy of Pediatrics. Poliovirus infections. In: Pickering L K, editors. Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000 p. 465-70.
80. Kohler KA, Banerjee K, Garg Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: Decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002; 80: 210-6.
81. John TJ. Vaccine-associated paralytic poliomyelitis in India. Bull World Health Organ 2002; 80: 917.
82. Kew O, Maurice-Glasgow V, Landaverdo M, Burns C, Show J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296: 356-59.
83. Centers for Disease Control and Prevention. Circulation of a type 2 vaccine-derived poliovirus-Egypt 1982-1993. MMWR Morb Mortal Wkly Rep 2001; 50: 41-2, 51.
84. Centers for Disease Control and Prevention. Public Health Despatch: Acute flaccid paralysis associated with circulating vaccine-derived poliovirus - Philippines 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 874-5.
85. John TJ. Polio eradication in India: What is the future? Indian Pediatr 2003; 40: 455-62.
86. John TJ. The final stages of global eradication of polio. N Engl J Med 2003; 343: 806-7.